A new analysis found that the profound benefits of Novo Nordisk’s obesity drug Wegovy for people at risk of heart attacks or strokes don’t depend on the number of the scale—cardiovascular health improves whether people lose a lot or even very little weight. That message adds needed nuance to our understanding of the health effects of the new class of medicines known broadly as GLP-1 drugs. It also raises a critical question: Could these drugs, which also include Eli Lilly & Co.’s Mounjaro, one day shake the “obesity” label and Read More
No comments:
Post a Comment